Innovative skincare technology secures new license agreemen
Blis Technologies Limited: Ground Floor, 442 Moray Place, Dunedin Central 9016, PO Box 2208, Dunedin 9044, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
16 August 2023
Innovative skincare technology secures new license agreement
Blis Technologies (NZX: BLT) is pleased to announce the signing of an agreement with a significant
Australasian cosmetic skincare company to licence our cosmetic facial live probiotic serum
containing BLIS Q24®. The agreement allows for exclusive marketing of the Blis developed serum
formulation under the partner’s brand domestically and in export markets where the partner has a
significant presence in both retail and online sales.
Further details of the agreement and relationship cannot be disclosed at this time to maintain
confidentiality.
Blis CEO Brian Watson said “We are excited to have finalised this first Business to Business
relationship for our skincare technology. Our strategy has been to secure partnerships with
established regional brands who have the capability to launch this breakthrough product in selected
markets. This relationship further validates the value of our innovation and the exciting future for
our skincare focus.”
What this agreement means for Blis:
• Recognition of Blis’ world class innovation in cosmetic skincare
• The first B2B initiative for skincare, in line with our revised strategy of targeting partnerships
with established cosmetic skincare companies
• New ingredient revenue and technology licensing royalties expected to have a small positive
impact on earnings in FY24 and solid growth in the following years
Ends
For further information, please contact:
Brian Watson
CEO
+64 27 705 9133
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout New Zealand
and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.
Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9012, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz
About the BLIS Q24™ Live Probiotic Serum
Enriched with a live probiotic in a shelf-stable topical format, the BLIS Q24™ Live Probiotic Serum is proven
to address various skin concerns and help to maintain a healthier, more radiant complexion.
BLIS Q24™ is a patented strain of Micrococcus luteus, a commensal and beneficial species of bacteria
naturally found in the skin. The strain was isolated in 2004 by Professor Emeritus John Tagg, who
recognised its unparalleled ability to inhibit the growth of key skin pathogens that can cause damage to
human skin.
Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- BIF — Booster Innovation Fund: BIF – Quarterly Client Update2023-10-11
“Portfolio Highlights Portfolio company, BioLumic, has successfully partnered with seed and seedling producers based in the United States that are growing plant types including Corn, Soybean, and Cannabis. Their revolutionary UV technology delivers ultraviolet light to seeds a…”
- PEB — Pacific Edge Limited: Quarterly Update – Q2 24 Cxbladder Test Volumes Resilient2023-10-10
“11 October 2023 CXBLADDER TEST VOLUMES RESILIENT IN THE FACE OF HEADWINDS DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) announces test volumes processed at its laboratories in the second quarter of the 2024 financial year (Q2 24) fell 12% to…”
- PEB — Pacific Edge Limited: Correction of LCD Reference Number2023-07-07
“6 July 2023 PACIFIC EDGE WELCOMES STAY OF NOVITAS LCD DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today welcomes a decision from Novitas 1 and First Coast to delay the implementation of the Local Coverage Determination (LCD, L393…”